{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:42:57Z","timestamp":1787024577395,"version":"build-2736575974"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,11,1]]},"DOI":"10.2169\/internalmedicine.1610-23","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T18:11:10Z","timestamp":1678817470000},"page":"3151-3156","source":"Crossref","is-referenced-by-count":4,"title":["Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab"],"prefix":"10.2169","volume":"62","author":[{"given":"Sanae","family":"Uehara","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Furuichi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Furusawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kaburagi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Naruse","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Tomaru","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Yasuoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tomioka General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"},{"name":"Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet 397: 428-444, 2021.","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281, 2010.","DOI":"10.1056\/NEJMoa0908721"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103: 469-474, 2010.","DOI":"10.1038\/sj.bjc.6605779"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30: 1950-1958, 2019.","DOI":"10.1093\/annonc\/mdz402"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ioka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci 2022.","DOI":"10.1002\/jhbp.1219"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1: 2022.","DOI":"10.1056\/EVIDoa2200015"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21: 1353-1365, 2020.","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"8","unstructured":"8. Foundation Medicine. FoundationOne CDx\u2122 Technical Information [Internet]. [cited 2022 Dec 26]. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170019C.pdf"},{"key":"9","unstructured":"9. Summary of Safety and Effectiveness Data (SSED) [Internet]. [cited 2022 Dec 26]. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170019S016B.pdf"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer 7: 183, 2019.","DOI":"10.1186\/s40425-019-0647-4"},{"key":"11","unstructured":"11. NCCN Clinical Practice Guideline: Biliary Tract Cancers. Ver 4. 2022 [Internet]. [cited 2022 Dec 29]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shao C, Li G, Huang L, et al. Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw Open 3: e2025109, 2020.","DOI":"10.1001\/jamanetworkopen.2020.25109"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31: 1491-1505, 2020.","DOI":"10.1016\/j.annonc.2020.07.014"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 7: 746-756, 2018.","DOI":"10.1002\/cam4.1372"},{"key":"15","unstructured":"15. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38: 1-10, 2020."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rousseau B, Foote MB, Maron SB, et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N Engl J Med 384: 1168-1170, 2021.","DOI":"10.1056\/NEJMc2031965"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. McGrail DJ, Pili\u00e9 PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32: 661-672, 2021.","DOI":"10.1016\/j.annonc.2021.02.006"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51: 202-206, 2019.","DOI":"10.1038\/s41588-018-0312-8"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/21\/62_1610-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:29:45Z","timestamp":1715560185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/21\/62_1610-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":18,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1610-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"article-number":"1610-23"}}